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Abstract 
The occurrence of non-epileptic hyperkinetic movements in the context of developmental epileptic 
encephalopathies is an increasing recognised phenomenon. Identification of causative mutations provides an 
important insight into common pathogenic mechanisms that cause both seizures and abnormal motor control. 
We report biallelic loss-of-function CACNA1B variants in six children from three unrelated families presenting 
with a complex and progressive neurological syndrome. All affected individuals presented with epileptic 
encephalopathy, severe neurodevelopmental delay (often with regression), and a hyperkinetic movement 
disorder. Additional neurological features included postnatal microcephaly and hypotonia. Five children died 
in childhood or adolescence (mean age of death, 9 years), mainly due to secondary respiratory complications. 
CACNA1B encodes the pore-forming subunit of the pre-synaptic neuronal voltage-gated calcium channel 
Cav2.2/N-type, crucial for SNARE-mediated neurotransmission, particularly in the early postnatal period. 
Biallelic loss-of-function variants in CACNA1B are predicted to cause disruption of Ca2+ influx, leading to 
impaired synaptic neurotransmission. The resultant effect on neuronal function is likely to be important in the 
development of involuntary movements and epilepsy. Overall, our findings provide further evidence for the 
key role of Cav2.2 in normal human neurodevelopment.      
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Main Text 
The developmental and epileptic encephalopathies (DEE) are a heterogeneous group of complex disorders 
characterised by severe early-onset seizures that are typically refractory to medication and associated with 
neurodevelopmental delay, regression and often multiple co-morbidities.1,2,3 To date, advances in next-
generation sequencing have facilitated the identification of over 150 monogenic causes of DEE. A broad range 
of pathophysiological processes have been identified, including disturbance of synaptic function, impaired 
neurotransmitter release, ion channelopathies, dysregulation of gene transcription, abnormal DNA repair, 
peroxisomal defects, mitochondrial dysfunction, impaired transporter activity and defective cell signalling and 
adhesion.1 The majority of mutations implicated in DEE occur in genes widely expressed throughout the 
central nervous system, with key roles in neuronal function. It is therefore not surprising that DEE is commonly 
associated with additional disease features, including neurodevelopmental delay, intellectual disability, motor 
difficulties, microcephaly, autistic features and behavioural issues. More recently, non-epileptic movement 
disorders have been increasingly recognised in individuals with DEE.4,5 Indeed, hyperkinetic movement 
phenotypes, such as  dystonia and choreoathetosis, are now commonly reported in individuals with FOXG1- 
(MIM:164874), GNAO1- (MIM:139311), SCN8A- (MIM:600702) and STXBP1- (MIM: 602926) related epilepsy-
dyskinesia syndromes.6–9 
We report the identification of biallelic CACNA1B variants in six children from three families presenting with 
DEE associated with a severe hyperkinetic movement disorder (Figure 1a-c). Over the last decade, we have 
recruited 494 children with DEE of unknown aetiology for detailed endophenotyping and molecular genetic 
investigation. Of these, 61 had a prominent non-epileptic hyperkinetic movement disorder (Table S1) with 
dystonia, choreoathetosis, or generalised dyskinesia.  Molecular genetic studies were approved by the local 
ethics committee (REC 13/LO/0168) and written informed consent was obtained from all participating 
families. Through multigene panel testing and whole exome or whole genome sequencing, an underlying 
genetic cause was identified in 20 of these individuals with DEE-dyskinesia phenotypes (Table S1). 
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Within the cohort of 41 unsolved cases, we identified a consanguineous family of Pakistani origin (first cousin 
parents) with 3 similarly affected children presenting with DEE and a hyperkinetic movement disorder (Family 
A, Table 1, Figure 1a). There was no history of neurological or metabolic disorders within the extended family.  
All children were born following an uncomplicated pregnancy and had a normal birth history. Affected 
individual A-II:2 had a period of normal development and by 8 months of age, he was able to sit unsupported 
and babbled. There were some concerns immediately prior to the onset of seizures with regards to hypotonia, 
poor visual fixation, nystagmus, and slowing of developmental milestones. At age 10 months, he had onset of 
epileptic spasms with >100 episodes per day, and electroencephalogram (EEG) confirmed the presence of 
hypsarrhythmia. Seizures were refractory to medical treatment, (tonic seizures, flexor spasms and myoclonus) 
and EEG consistent with Lennox-Gastaut syndrome. With the onset of seizures, there was concurrent 
regression of previously acquired skills, with development of severe intellectual disability (ID), postnatal 
microcephaly, a hyperkinetic movement disorder and bulbar dysfunction. The hyperkinetic movement 
disorder was characterized by a combination of dystonia and severe non-epileptic myoclonus, with frequent 
exacerbations.  His siblings (A-II:3 and A-II:4) followed an almost identical course, with onset of epilepsy and 
developmental regression at the age of 9 and 10 months respectively (Table 1, Figure 1a). Extensive diagnostic 
neurometabolic work-up failed to identify an underlying cause (Table S2). Electroencephalogram showed 
changes consistent with epileptic encephalopathy (Figure 1d,e). Brain magnetic resonance imaging (MRI) 
showed non-specific findings of cerebral atrophy in affected individual A-II:2 (age 12 months) and asymmetry 
of temporal horns and white matter signal changes in individual A-II:3 (age 24 months). Neuroimaging was 
normal in individual A-II:4 at age 14 months. 
Genome-wide linkage studies were undertaken in Family A (II:2, II:3, II:4) using Affymetrix 250K Sty1 SNP 
mapping array (Affymetrix, Inc., Santa Clara, CA). Genotype data was processed with Genomestudio (Illumina 
Inc.) and subsequently analyzed using both homozygosity mapper and manually in Microsoft Excel.10 Eight 
common regions of homozygosity (>2Mb) were initially identified (Table S3). These regions were further 
evaluated in all family members using microsatellite markers.  Linkage to two regions on chromosome 14 and 
21 were excluded by detection of similarly homozygous alleles in unaffected individuals, leaving six potential 
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disease loci (Table S4, Figure S1,2). Whole exome sequencing was performed on affected individual A-II:4 
using SureSelect All Exon 50Mb Target Enrichment System/SureSelect human All Exon kit (v2; Agilent 
Technologies), according to manufacturer’s recommendations. Data were analysed following Genome 
Analysis Toolkit’s (GATK) Best Practices. A total of  23,158 variants were identified, that were further prioritized 
as follows: (i) those within the six regions of homozygosity; (ii) non-synonymous, frameshift, splice site, and 
nonsense changes; (iii) absent or only observed at a very low frequency in control populations (exclusion of 
variants with minor allele frequency of >0.01% in publically available databases, including dbSNP, 1000 
Genomes, Exome Variant Server (EVS) and gnomAD; (iv) affecting highly conserved amino acids; and (v) 
missense changes predicted to be damaging by at least one prediction program (PolyPhen-2, SIFT, PROVEAN 
or MutationTaster). Using these criteria, 3 homozygous variants were identified as follows; CACNA1B 
(GenBank:NM_000718.4; c.3665del, p.Leu1222Argfs*29, Chr9:140943722), TSHB (GenBank:NM_000549.3; 
c.223A>G, p.Arg75Gly) and DPP7 (GenBank: NM_00013379; c.1343+5G>A) (GRCh37/hg19) (Table S5).  The 
TSHB variant was predicted to be benign by multiple in-silico programs. The DDP7 variant was predicted to be 
a polymorphism in MutationTaster with minimal effect on splicing (MaxEnt Scan, NN Splice, human splicing 
finder [HSF]). The CACNA1B variant, a homozygous 1bp deletion predicted to cause a frameshift and 
premature truncation, was predicted to be deleterious. The variant was absent in gnomAD, 1000 genomes, 
Exome Variant Server (EVS), and in-house exomes (N=250). In the ExAC database, CACNA1B is predicted to be 
extremely intolerant of loss-of-function, with a pLi score of 0.98.11  Direct Sanger sequencing was performed, 
confirming whole exome sequencing findings, with appropriate segregation of the mutation in the family 
(Figure 1a).  Unaffected sibling (A-II:1) was not sequenced. Whole exome sequencing data from individual A-
II:4 was also probed for 154 DEE-related genes, but no potentially pathogenic variants were identified (Tables 
S6,7). 
The remaining affected individuals in the epilepsy cohort were screened for CACNA1B variants by either 
analysis of available whole exome/genome data or through targeted CACNA1B sequencing with a custom 
amplicon array (TruSeq). No further cases were identified.  We submitted the variant to GeneMatcher and 
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requested collaborating research groups to probe their whole exome and genome datasets (Table S8). 
Through these routes, we identified two further families with biallelic CACNA1B variants.  
A second British family with two affected children (Family B, Figure 1b) harbouring compound heterozygous 
variants in CACNA1B was identified from the UK10K Genome project.12 Both children had a 2bp deletion 
creating a frameshift (c.3573_3574del, p.Gly1192Cysfs*5, chr9:140941880) and a splice-site variant in the 
donor splice site of intron 34 (c.4857+1G>C, chr9:140968519). MaxEnt Scan, NN Splice, HSF and BDGP fruit 
fly, all predict 100% loss of donor site, resulting in skipping of exon 34. Both variants are absent from control 
databases (gnomAD, 1000 Genome, and EVS). No other variants in known genes causing neurological disorders 
were identified. Sanger sequencing confirmed the two variants in both children (Figure 1b). The c.4857+1G>C 
variant was detected as a heterozygous change in the mother. Paternal DNA was unavailable for genetic 
testing.  The children from Family B were found to have a clinically similar phenotype to those in Family A 
(Table 1). Both boys were born to non-consanguineous parents of European descent with no pertinent family 
history, both born after an uneventful antenatal and birth history. Affected individual B-II:1 had pre-existing 
developmental delay prior to onset of epilepsy at age 2.5 years, with regression of previously acquired skills 
before the onset of epilepsy. He had a number of different seizure types including myoclonic, focal and 
generalised tonic-clonic (GTC) seizures, which were refractory to multiple anti-seizure medications.  A complex 
hyperkinetic movement disorder, characterised by dystonic posturing, choreoathetosis and dyskinesia 
emerged at 2.5 years. The movement disorder was drug-resistant, and associated with frequent 
exacerbations, leading to significant impairment of daily living activities and quality of life.   His younger 
brother (Individual B-II:2) had a similar presentation, with severe developmental delay, before the onset of 
epilepsy at age 21 months.  Epilepsy was refractory to conventional anti-seizure medications. EEG 
abnormalities were seen as a burst-suppression pattern in sleep and high amplitude multi-focal spike and 
wave activity when awake. (Figure 1f,g). At age 21 months, he developed a prominent complex hyperkinetic 
movement disorder with features of dystonia, choreoathetoid movements, non-epileptic myoclonus and 
hand-wringing stereotypies. Both children had additional neurological features including microcephaly, 
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hypotonia, visual impairment and severe cognitive difficulties. Both died, at age 17 years and 5 years 
respectively, from secondary respiratory complications.  
A third family with a single affected proband (Family C, Figure 1c) was identified through GeneMatcher.13 A 
homozygous variant (c. 1147 C>T, p. Arg383*, Chr9:140850226) in CACNA1B was identified through a 
commercial clinical exome and confirmed on Sanger sequencing (Figure 1c). The proband (C-II:1) of Bulgarian 
origin was adopted, and familial segregation studies were not possible. This variant was located within an area 
of extended SNP homozygosity (Table S9).  A variant in MMACHC (GenBank: NM_015506.2, c. 506T>C, p. 
Ile169Thr, Chr1:45974544) was also identified but was excluded as the proband’s serum homocysteine and 
urine organic acids were normal and multiple in-silico programs predicted the variant to be benign (Table S10).  
No other candidates were identified from the clinical exome, despite targeted analysis of 117 DEE genes (Table 
S11). Details of the birth, early medical history and developmental milestones are unavailable.  She was first 
reviewed by Paediatric Neurology services at aged 4 years, presenting with refractory epilepsy (epileptic 
spasms and tonic seizures), a hyperkinetic movement disorder (non-epileptic myoclonus and chorea) and 
global neurodevelopmental delay. EEG at first review, aged 4 years, was consistent with an epileptic 
encephalopathy with features of high amplitude, disorganised background (with no normal awake 
architecture), frontally dominant sharp slow waves of 1-2Hz, tonic seizures and epileptic spasms captured. 
Magnetic resonance imaging of the brain showed subtle asymmetry of the frontal lobes with a unilateral deep 
and linear appearing sulcus of the anterior left frontal lobe (Figure S3). Now aged 6 years, she has developed 
microcephaly, hypotonia, severe intellectual disability, and is fed via gastrostomy (Table 1).   
We have identified biallelic loss-of-function variants of CACNA1B in six children from three families with DEE 
associated with a severe hyperkinetic movement disorder. Voltage-gated calcium channels (VGCC) have a key 
role in neurons, mediating Ca2+ ion influx into excitable cells in response to membrane depolarisation, and 
thereby regulating a number of calcium-dependent processes, including neurotransmitter release, gene 
transcription, calcium-dependent enzymes and muscle contraction.14–20 To date, ten subtypes of VGCC have 
been identified, differentiated by varying voltage and pharmacological properties. VGCC are classified into 
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three subfamilies by sequence similarity (CaV1, CaV2, and CaV3). In neurons, the pre-synaptic CaV2 channel 
family, comprising Ca
V
2.1, Ca
V
2.2, and Ca
V
2.3 isoforms (termed P/Q-type, N-type, and R-type calcium 
channels) are encoded by CACNA1A, B and E respectively.14–16 
CACNA1B (Chr9:137,877,788-138,124,623 (GRCh38), MIM: 601012) encodes the calcium channel voltage-
dependent, N-type, α-1B subunit, the pore-forming subunit of presynaptic neuronal voltage-gated calcium 
channels (Cav2.2). Cav2.2 is expressed throughout the central nervous system including the cerebral white 
matter, cortex, hippocampus, basal ganglia and cerebellum (Figure S4).21–23 The expression pattern, especially 
in the basal ganglia and cerebellum, may bear relevance to the observed clinical manifestations associated 
with genes encoding calcium channel subunits,24 given that all reported affected individuals had epilepsy and 
hyperkinesia as a major part of their clinical phenotype.  
Cav2.1 and Cav2.2 synergistically modulate presynaptic Ca
2+ 
levels, thereby regulating SNARE-mediated release 
of neurotransmitters (monoamines, glutamate, GABA, serotonin).21 Cav2.2  is also postulated to have a role in 
synaptic plasticity, synaptogenesis, gene transcription, neuronal survival and migration of immature 
neurons.19,25 Expression of CACNA1B is thought to be crucial for neurotransmission in the early postnatal 
period, as Cav2.2 channels are replaced by Cav2.1 in mature synapses within the thalamus, cerebellum, and 
auditory brainstem.18,20  
Given the key neuronal functions of Cav2.1 and Cav2.2, over time there has been great interest regarding the 
potential role of these channels in neurological diseases. Our work now implicates a role for biallelic mutations 
of CACNA1B in DEE and movement disorders. Previously, a heterozygous CACNA1B missense variant 
(c.4166G>A, p.Arg1389His, rs184841813) was reported in a single Dutch family with five affected individuals 
presenting with adult-onset myoclonus-dystonia and cardiac arrhythmia (DYT-23, MIM: 614860).26  This 
finding has not been replicated in subsequent studies.27  Single nucleotide polymorphisms and heterozygous 
copy number variants involving CACNA1B have been described in individuals with neurovascular disorders and 
schizophrenia.28–30 Notably, heterozygous variants in the related gene, CACNA1A (MIM: 601011) are now an 
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established cause of early infantile epileptic encephalopathy (EIEE) (MIM: 617106), episodic ataxia type 2 
(MIM: 108500), familial hemiplegic migraine type 1 (MIM: 141500) and spinocerebellar ataxia type 6 (MIM: 
183086). Biallelic mutations in CACNA1A have also been reported in a single family with severe DEE, associated 
with progressive cerebral, cerebellar and optic atrophy.31–34 More recently, heterozygous missense mutations 
in CACNA1G (MIM: 604065) have been reported in childhood-onset cerebellar atrophy with EIEE, providing 
further evidence that disruption of calcium channels is a key pathogenic mechanism in DEE-related 
syndromes.35 
CACNA1B is organised in 4 homologous domains (DI-IV), each containing a motif of 6 transmembrane helices 
(S1-S6) and a P-loop between S5 and S6 (Figure 2).  The S5 and S6 segments and the P-loop represent the pore 
domain of the channel. The fourth segment (S4) of each domain is the voltage-sensor for activation. SNARE-
complex proteins interact directly through a specific synaptic protein site in the large intracellular loop 
connecting domains II and III (syniprint site). The intracellular linkers between domains I-II, II-III, N and C 
termini are important for channel regulation and interaction with other proteins, including Gβγ, protein kinase 
C (PKC) and PIP2.16,18,36 Variants reported in Family A and B are both located within DIII. The p. Arg380* (Family 
C) is in the intracellular linker between domain I-II, key for binding of Gβγ (Figure 2).18 All variants are predicted 
to cause loss-of-function through nonsense-mediated decay and/or protein truncation. Identification of 
further CACNA1B-mutation positive cases will determine mutation hot spots and any genotype-phenotype 
correlation. 
Cav2.2 channels have a key role in normal synaptic function. Soluble N-ethylmaleimide-sensitive factor 
activating protein receptor (SNARE) complexes (syntaxin, SNAP-25, VAMP and synaptobrevin) are key 
elements of vesicle trafficking, docking and presynaptic vesicle recycling in neuronal membranes.16,37–39 
Depolarisation of the pre-synaptic terminal initiates opening of Cav2.2 and subsequent influx of Ca2+ ions.  A 
rise in intracellular Ca2+ concentration is detected by Synaptotagmin-1 (SYT1), triggering fusion and 
subsequent exocytosis of the neurotransmitter vesicles through primed SNARE-protein complexes (Figure S5). 
We postulate that loss-of-function mutations in CACNA1B impair Ca2+ flux and normal synaptic transmission. 
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Effects on monoamine and GABA/glutamatergic networks may influence the development of epilepsy and 
abnormal motor control in affected children. Dysfunctional presynaptic vesicle recycling is emerging as a key 
cellular mechanism underlying epilepsy-dyskinesia phenotypes. Indeed, disease-causing variants in other 
SNARE or SNARE-regulatory proteins are increasingly recognised, including STXBP1 (EIEE MIM:612164, 
hyperkinetic movement disorder), STX1B (generalised epilepsy with febrile seizures MIM: 616172), GOSR2 
(progressive myoclonic epilepsy MIM: 614018), SYT-1 (early-onset dyskinesia and intellectual disability) and 
SNAP25 (epilepsy and intellectual disability).8,40–43  
CACNA1B is postulated to play a role in early brain development, as supported by the expression profile of 
Cav2.2.20 Cav2.2 knockout murine models manifest a number of neurodevelopmental abnormalities including 
abnormal locomotor activity and memory impairment.44 Future models of Cav2.2 dysfunction will be integral 
in further understanding the neurodevelopmental role of this protein.  
In summary, we report six affected individuals with biallelic loss-of-function variants in CACNA1B, and a 
neurodevelopmental disorder characterised by developmental and epileptic encephalopathy, postnatal 
microcephaly and a complex hyperkinetic movement disorder. Identification of further cases will provide more 
insight into the spectrum of neurological diseases associated with CACNA1B variants, as well as potential 
genotype-phenotype correlations.  The identification of CACNA1B further expands genetic heterogeneity in 
severe childhood epilepsy-dyskinesia syndromes.   
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Figure Legends 
Figure 1: Molecular genetic investigation and electroencephalogram features of affected individuals 
with biallelic CACNA1B Variants 
(a) Segregation of CACNA1B c.3665del variant in Family A shows all three affected children to be 
homozygous for the variant and parents to be heterozygous carriers of this variant (b) In Family B, the 
two affected individuals carried the two rare variants, c.3573_3574del, c.4857+1G>C. The mother is 
heterozygous for one of the variants. (c) For Family C, the affected child is homozygous for the c.1147 
C>T variant. Parental samples were not available. (d)-(g) EEG traces from affected individuals. EEG A-
II:3 showing epileptic encephalopathy; aged 3.75 years (d) with bilateral high-amplitude spike and 
wave discharges with spasm (arrow) and (e) aged 4.75 years with bilateral continuous high-amplitude 
spike and wave discharges maximal over central regions. EEG B-II:2 aged 9 years (HF filter,  70Hz; 
sensitivity, 15uV/mm; timebase, 30mm/sec) showing burst-suppression pattern in sleep (f) and fairly 
continuous, high amplitude, multi-focal spike and wave activity maximal over central regions during 
wakefulness (g). 
Figure 2: Schematic representation of Cav2.2 with location of CACNA1B variants  
The structure of Cav2.2 consists of four homologous repeats (domain I-IV) each containing 6 
transmembrane alpha-helices (S1-S6) and a P-loop between S5 and S6. The S5 and S6 helices and the 
P-loop represent the pore domain of the channel (green). The fourth segment (S4) of each domain is 
the voltage-sensor for activation. Gene variants identified in families A, B  and C are indicated in red 
(loss-of-function variants). The previously reported heterozygous missense variant associated with 
myoclonus-dystonia is highlighted in yellow. Gβγ, G Protein βγ subunit: P, Binding site of PKC; PKC, 
Protein Kinase C. 
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Tables 
 
Table 1 (overleaf): Key clinical characteristics of individuals with biallelic CACNA1B mutations 
 
a SNP array revealed ~30% areas of homozygosity, possibly suggestive of consanguinity 
Abbreviations: ACTH, adrenocorticotropic hormone; AED, anti-epileptic drug;  BIO, biotin; CBM, 
clobazam; CPM, clonazepam; CVI, cortical visual impairment; FOL, folinic acid; GER, gastro-esophageal 
reflux; GTC, generalised tonic clonic; L, left; LAC, lacosamide;  LEV, levetiracetam;  m, months; NPM, 
nitrazepam;  NR nil reported; OFC, occipitofrontal circumference; PHY, phenytoin; PIR, piracetam; R, 
right; RUF, rufinamide; TOP, topiramate; VBN, vigabatrin; VB6, vitamin B6 (pyridoxine); VPA, sodium 
valproate; y, years  
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 A-II:2 A-II:3 A-II:4 B-II:1 B-II:2 C-II:I 
Biallelic variants p.Leu1222Argfs*29/  
p.Leu1222Argfs*29 
p.Leu1222Argfs*29/  
p.Leu1222Argfs*29 
p.Leu1222Argfs*29/  
p.Leu1222Argfs*29 
p.Gly1192Cysfs*5/ 
c.4857+1G>C 
p.Gly1192Cysfs*5/ 
c.4857+1G>C 
p.Arg383*/ 
p.Arg383* 
Consanguinity Yes, 
Parents 1st cousins 
Yes, 
Parents1st cousins 
Yes, 
Parents 1st cousins 
No No Unknowna 
Ethnicity Pakistani Pakistani Pakistani European descent European descent European descent 
Age of Death (years) 
Cause of Death 
3y  
Respiratory infection 
7y  
Meningitis 
End organ failure 
14y 
Respiratory infection 
17y   
Respiratory 
infection 
5y 
Respiratory 
infection 
Alive – 6y 
Sex Male Male Female Male Male Female 
Pregnancy 
Birth 
Normal 
Term, normal 
Normal 
Term, normal  
Normal 
36 weeks, normal 
Normal 
Term, normal  
Normal 
Term, normal  
Unknown 
Unknown 
Best 
Neurodevelopmenta
l stage (age) 
Sat with support, 
babbled and smiled 
(8m) 
Sat unsupported, 
reached for objects 
and babbled (9m) 
Sat with support and 
smiled (8m) 
Sat unsupported, 
1 word  (2y) 
Always delayed 
Never sat/babbled 
Always delayed 
Never sat 
Age of regression 10m 10m 8m  2y Always delayed Unknown 
Age of seizure onset 10m 9m 12m 30m 21m Unknown 
Seizure type 
At presentation  
evolution over time 
Epileptic spams  
(100 cluster 
spasms/day)  
Tonic, myoclonic, 
flexor spasms 
Epileptic spasms 
GTC, myoclonic, 
tonic 
Epileptic spasms 
Myoclonic, GTC, 
flexor spasms, focal 
Daily clustering  
Myoclonic   
Focal, GTC, 
myoclonic 
Daily episodes 
Myoclonic, focal, 
GTC 
Daily 
Epileptic spasms 
Tonic 
 
Medications tried 
(medications with 
some beneficial 
effect underlined) 
NPM, PHY, Steroids,  
VB6,VBN, VPA 
 
 
Refractory to AED 
CBM,  VBN, VPA  
 
 
 
Periods of seizure 
freedom on CBM and 
VBN 
ACTH, CBM, LAC, 
LEV, NPM, PHB, 
Steroids,  RUF,  TOP, 
VBN, VPA 
Non-sustained 
response to some 
drugs, generally 
refractory 
CBM, FOL, LAC, 
LEV, LTG, PIR, TOP, 
VB6, VPA 
 
Refractory to AED 
BIO, CPM, FOL, 
LEV, LTG, PIR, VB6, 
VPA 
 
 
Refractory to AED 
CBM, LEV, PHB, RUF, 
Steroids 
 
 
6m seizure free on PHB 
and RUF 
Movement disorder Myoclonus 
Dystonia  
Episodic 
exacerbations 
Myoclonus 
Dystonia  
Myoclonus  
Dystonia 
Oromotor dyskinesia 
Myoclonus 
Dystonia  
Choreoathetosis 
Dyskinesia 
Frequent 
exacerbations 
Myoclonus 
Dystonia 
Choreoathetosis 
Hand-wringing 
stereotypies  
Myoclonus  
Choreoathetosis 
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Other features 
Head size 
 
 
 
Vision 
 
 
 
 
 
Central and 
peripheral tone 
 
 
 
Gastrointestinal 
 
 
Respiratory 
 
 
 
 
Other 
 
Postnatal 
microcephaly  (OFC 
0.4th centile) 
 
Strabismus 
Nystagmus 
 
 
 
 
Central hypotonia 
and brisk limb 
reflexes 
 
 
Enteral feeding 
 
 
Recurrent 
respiratory infections 
 
 
 
NR 
 
Postnatal 
microcephaly  
(OFC 0.4th centile) 
 
 
 
 
 
 
 
Central hypotonia 
with increased 
peripheral tone L>R 
 
 
Enteral feeding 
 
 
Recurrent 
respiratory infections 
 
 
 
NR 
 
Postnatal 
microcephaly  
 (OFC 3rd centile) 
 
Left strabismus 
CVI 
 
 
 
 
Generalised 
hypotonia 
 
 
 
Enteral feeding 
GER 
 
Recurrent 
respiratory infections 
 
 
 
Conductive deafness 
 
Postnatal 
microcephaly  
(OFC  <0.4th 
centile) 
CVI 
 
 
 
 
 
Generalised 
hypotonia 
 
 
 
Enteral feeding  
 
 
Recurrent 
respiratory 
infections 
 
 
Periods of 
agitation 
 
Postnatal 
microcephaly  
(OFC 2nd centile) 
 
Divergent 
strabismus 
Congenital 
nystagmus 
CVI 
 
Generalised 
hypotonia 
 
 
 
Enteral feeding 
GER 
 
Recurrent 
respiratory 
infections 
Stridor 
 
Bruxism 
 
Microcephaly (not known 
whether congenital or 
postnatal) 
(OFC 2nd centile)  
 
 
 
 
 
 
Generalised hypotonia 
 
 
 
 
Enteral feeding 
GER 
 
NR 
 
 
 
 
NR 
Dysmorphic features Right talipes at birth NR Dislocated L hip at 
birth 
Small testis  
Anteverted nares 
Thickened gums 
Slim hands/feet  
2/3 syndactyly 
Small testis NR 
 
